BridgeBio Pharma Grows Pipeline to 20+ Genetic Medicines with Four Assets Focused on Treating Genetically Driven Diseases at Their Source

New assets span multiple modalities and target an endocrine disorder, inherited eye disease, genetically driven deafness and autism spectrum disorder SAN FRANCISCO – January 13, 2020 – BridgeBio Pharma, Inc. (NASDAQ: BBIO) today disclosed four additional assets in its pipeline, expanding the number of disclosed programs to over 20 potential medicines. BridgeBio’s world-class team of […]

BridgeBio Pharma’s Gene Therapy Subsidiaries Enter Strategic Partnership with Catalent for Dedicated Gene Therapy Development and Manufacturing Capacity

The deal is designed to accelerate BridgeBio’s gene therapy programs The dedicated suite will support clinical and commercial supply needs for BridgeBio’s gene therapy programs for congenital adrenal hyperplasia (BBP-631) and Canavan disease (BBP-812) PALO ALTO, Calif. – January 10, 2020 – BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration agreement with Catalent to […]

PellePharm Initiates Phase 2 Clinical Trial of Patidegib Topical Gel for People with High Frequency Basal Cell Carcinoma

SAN FRANCISCO – January 8, 2020 – PellePharm, Inc., a BridgeBio Pharma, Inc. (Nasdaq: BBIO) company, today announced it has dosed the first two participants in a Phase 2 clinical trial of Patidegib Topical Gel, 2%, vs. vehicle gel for people with non-Gorlin High-Frequency Basal Cell Carcinoma (HF-BCC). HF-BCC is a rare disease that causes a […]

BridgeBio Pharma’s QED Therapeutics Receives Fast Track Designation for Infigratinib in Adults with First-Line Advanced or Metastatic Cholangiocarcinoma and Orphan Drug Designation for Infigratinib for Treatment of Cholangiocarcinoma

The PROOF trial, a Phase 3 trial of infigratinib in first-line cholangiocarcinoma, is currently enrolling SAN FRANCISCO – January 6, 2020 – BridgeBio Pharma, Inc. (Nasdaq: BBIO) subsidiary QED Therapeutics announced today that it has secured both Fast Track Designation in adults with first-line advanced or metastatic cholangiocarcinoma and Orphan Drug Designation for infigratinib for […]

BridgeBio Pharma, Inc. To Present At Upcoming Investor Conference

PALO ALTO, Calif., December 19, 2019 – BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced today that it will present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 3 PM (PST) in San Francisco. The presentation will be webcast live and can be accessed at www.bridgebio.com on the For Investors page […]

BridgeBio Pharma’s Origin Biosciences Enters Partnership with Medison To Commercialize BBP-870 In Israel for MoCD Type A

BOSTON, December 18, 2019 – BridgeBio Pharma, Inc. (Nasdaq: BBIO) subsidiary Origin Biosciences, a company focused on developing and commercializing a treatment for Molybdenum Cofactor Deficiency (MoCD) Type A, and Medison Pharma Ltd., a leading commercial biotech partner that operates in Israel, Canada and Central and Eastern European countries, have entered into an exclusive license […]

BridgeBio Pharma, Inc. Appoints Industry Leader Jennifer Cook as New Board Member

Genentech veteran brings global commercial expertise to Board of Directors and will serve as a Special Advisor PALO ALTO, Calif., December 16, 2019 — BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced it has appointed Jennifer Cook to its Board of Directors and will leverage her considerable expertise as a special advisor to the senior management […]

BridgeBio Pharma, Inc. Appoints Eli Wallace as Chief Scientific Officer in Residence for Oncology Programs

Dr. Wallace brings over two decades of experience in oncology drug discovery to leadership team PALO ALTO, Calif. – December 9, 2019 – BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, announced it has appointed Eli Wallace, Ph.D., as its chief scientific officer in residence for oncology effective immediately. In […]

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Palo Alto, CA, December 5, 2019 — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on November 22, 2019, the compensation committee of BridgeBio’s board of directors granted eight new employees options to purchase an aggregate of 62,745 shares of the Company’s common stock with a per […]

BridgeBio Pharma’s Origin Biosciences Initiates Rolling Submission Of New Drug Application With The U.S. FDA For BBP-870 For The Treatment Of MoCD Type A

BOSTON, December 3, 2019 – BridgeBio Pharma, Inc. (Nasdaq: BBIO) subsidiary Origin Biosciences has initiated a rolling submission of a New Drug Application (NDA) with the United States Food and Drug Administration (FDA) for fosdenopterin (BBP-870/ORGN001) for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A. Currently, there are no approved therapies that […]